Latest News for: kras

Edit

PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader

PR Newswire 22 Jan 2026
Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ's KRAS G12D degrader, as well as the clinical advancement of PT0511 ... PT0511 is a pan-KRAS degrader designed to target multiple oncogenic KRAS variants.
Edit

Royal Hospital achieves breakthrough with colorectal cancer diagnostic testing

Muskat Daily 20 Jan 2026
This development, led by the Department of Medical Laboratories and the Histology and Cytology Section, marks the first time that specific genetic tests—KRAS, NRAS, and BRAF—have been performed within the Sultanate of Oman ... ....
Edit

KRAS Inhibitors Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Pfizer, Roche, Chugai, ...

GetNews 08 Jan 2026
To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;. Some of the key facts of the KRAS Inhibitors Market Report. ... G12C is the most commonly detected KRAS mutation in NSCLC.
Edit

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, ...

Image Rutland Herald 07 Jan 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Jan 7, 2026-- ....
Edit

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Pharmiweb 07 Jan 2026
Third Phase 3 trial in Merck’s KANDLELIT clinical development program, which is investigating calderasib in KRAS G12C-mutant cancers across multiple tumor types and treatment settings ... KRAS is the most ...
Edit

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Form 8-K) (Verastem Inc)

Public Technologies 31 Dec 2025
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer ... KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors.
Edit

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C ...

Image The Joplin Globe 30 Dec 2025
BOSTON--(BUSINESS WIRE)--Dec 29, 2025-- ... .
Edit

Extension for Upload of Client Records to KRAs for Validations (MCX - Multi Commodity Exchange of India Ltd)

Public Technologies 25 Dec 2025
Extension for Upload of Client Records to KRAs for Validations ... Non-upload of KYCs to KRAs is a non- compliance with the aforementioned regulatory requirements ... The KRA status of the said PANs shall be verified with the respective KRAs.
Edit

Extension for Upload of Client Records to KRAs for Validations (BSE Ltd)

Public Technologies 24 Dec 2025
Subject Extension for Upload of Client Records to KRAs for Validations ... Extension for Upload of Client Records to KRAs for Validations<_o3a_p> ... The KRA status of the said PANs shall be verified with the respective KRAs.
Edit

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

Image The Galveston Daily News 21 Dec 2025
... AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73.
Edit

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS ...

Nasdaq Globe Newswire 16 Dec 2025
$2.7M NIH grant evaluates TRE-515 with KRAS inhibitors in lung cancer, boosting Trethera’s FDA Fast Track pipeline with a novel approach to resistance ... .
Edit

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Business Wire 16 Dec 2025
... cancer (“mCRC”), specifically in patients with KRAS-mutant, microsatellite-stable (“MSS”) disease.
Edit

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Form 6-K) (Oncolytics Biotech Inc)

Public Technologies 16 Dec 2025
) Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer. 33% ORR achieved in second-line KRAS-mutant MSS colorectal ...
Edit

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast ...

Nasdaq Globe Newswire 12 Nov 2025
G12C is the most prevalent KRAS mutation in NSCLC, making it a key target of current therapies. Following the success of KRAS G12C inhibitors, attention is shifting to KRAS G12D as the next major target.
Edit

Global KRAS Inhibitors Market Set to Surge at 35% CAGR by 2034 Across the US, ...

GetNews 10 Nov 2025
"Global KRAS Inhibitors Market" ... KRAS (Kirsten Rat Sarcoma viral oncogene) is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS ... Among the three RAS genes, KRAS, NRAS, and HRAS-KRAS is the most frequently mutated.

Article Search

tools
×
×
×
×